Disrupted terminal bilirubin catabolism links Lachnospiraceae depletion to inflammatory bowel disease
Frontiers in Microbiology · 17.08.2026 · 17
DOI: 10.3389/fmicb.2026.1871609 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 17.08.2026. Verfasst von Omer Sabti und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Ben Gurion University of the Negev, Be'er Sheva, Israel. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The gut microbiome mediates the reductive catabolism of bilirubin into urobilinoids, yet the bacteria and enzymes responsible for the later steps of this pathway remain largely unknown.
Methods
Here, we combine untargeted UPLC/HRMS metabolomics with shotgun metagenomic sequencing of fecal samples from 119 participants, including patients with Crohn’s disease, ulcerative colitis, and healthy controls, to map disruptions in the bilirubin catabolic pathway in inflammatory bowel disease (IBD).
Results
We show that stercobilinogen and stercobilin, the terminal metabolites of this pathway, are depleted ( p < 0.01) in IBD patients irrespective of disease subtype, while upstream intermediates, D-urobilinogen, remain unchanged. This metabolic bottleneck coincides with a marked reduction in members of the Lachnospiraceae family, specifically Blautia sp. SG-772 and three uncharacterized species, which show strong positive correlations with stercobilinogen and stercobilin levels.
Discussion
These findings implicate Lachnospiraceae as key mediators of the yet unknown enzymatic conversion of I-urobilinogen to stercobilinogen, extending the family’s known metabolic repertoire beyond short-chain fatty acid production. Given that bilirubin and its reduced metabolite stercobilinogen possess antioxidant properties, their depletion may contribute to the oxidative burden in the IBD gut. Conversely, the concurrent elevation of D-urobilin, which lacks these protective properties and has been linked to metabolic dysfunction in other contexts, may further exacerbate inflammation. Our results identify fecal bilirubin metabolites as candidate biomarkers of microbial dysbiosis in IBD and nominate specific Lachnospiraceae taxa for functional characterization of the missing stercobilinogen reductase.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemistry, Ben Gurion University of the Negev, Be'er Sheva, Israel.
- Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
- Department of Life Sciences, Ben Gurion University of the Negev, Be'er Sheva, Israel.
- Department of Gastroenterology, Soroka University Medical Center, Be'er Sheva, Israel.
- Division of Microbiome and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Zitieren
APA
Sabti, O., Lialin-Tzadikov, K., Ivanova, V., Dori-Bachash, M., Uzi-Gavrilov, S., Tik, Z., Mashiach, R., Zorea, A., Mizrahi, I., Segal, A., Moyal-Attias, K., Elinav, E., & Meijler, M. M. (2026). Disrupted terminal bilirubin catabolism links Lachnospiraceae depletion to inflammatory bowel disease. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1871609
Vancouver
Sabti O, Lialin-Tzadikov K, Ivanova V, Dori-Bachash M, Uzi-Gavrilov S, Tik Z, et al. Disrupted terminal bilirubin catabolism links Lachnospiraceae depletion to inflammatory bowel disease. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1871609
BibTeX
@article{Sabti2026,
author = {Sabti, Omer and Lialin-Tzadikov, Ksenia and Ivanova, Valeria and Dori-Bachash, Mally and Uzi-Gavrilov, Shaked and Tik, Zohar and Mashiach, Roi and Zorea, Alvah and Mizrahi, Itzhak and Segal, Arik and Moyal-Attias, Keren and Elinav, Eran and Meijler, Michael M},
title = {Disrupted terminal bilirubin catabolism links Lachnospiraceae depletion to inflammatory bowel disease},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1871609}
}
EUVIMED